Key facts
- This page summarizes Jeffrey L. Edwards's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2024, 18:35.
Jeffrey L. Edwards - 01 Feb 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
- Reporting relationship
- Director
- Issuer ticker
- LFCR
- Reported as of
- 01 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2024, 18:35:44 UTC
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 06 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron Perlitsh, Attorney-In-Fact for Jeffrey Edwards
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey L. Edwards filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 02 Feb 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LFCR
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,554
- Change %
- +24%
- Price
- Shares after
- 49,667
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LFCR
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -9,554
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,554
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2
The restricted stock units vested on February 1, 2024.